High Expression Levels of the Long Non-Coding RNAs Lnc-IRF2-3 and Lnc-KIAA1755-4 Are Markers of Poor Prognosis in Chronic Lymphocytic Leukemia

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(3), P. 1153 - 1153

Published: Jan. 29, 2025

Long non-coding RNAs (lncRNAs) play complex roles at multiple levels of gene regulation, thus modulating key cellular processes involved in the pathogenesis and progression cancer. Aberrant expression lncRNAs has been reported various malignancies, including chronic lymphocytic leukemia (CLL). We investigated lnc-IRF2-3 lnc-KIAA1755-4 peripheral blood mononuclear cells 112 previously untreated CLL patients by quantitative reverse-transcriptase polymerase chain reaction. Both were found to be overexpressed samples comparison healthy controls, their high associated with adverse clinico-biological characteristics diagnosis. High was leukocyte lymphocyte counts, β2-microglobulin, advanced Binet stage, unfavorable cytogenetics, CD38-positivity IGHV-unmutated status. Regarding lnc-KIAA1755-4, its count, lactate dehydrogenase low hemoglobin, as well In addition, we observed shorter time first treatment overall survival expressing both low-expressing patients. summary, our study showed that diagnosis predicts poor CLL. The mechanisms upregulation, specific targets cells, remain elucidated.

Language: Английский

---

Engineered ATP-Loaded Extracellular Vesicles: A Dual-Functional Strategy for Improving Myocardial Infarction Therapy

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: May 6, 2025

Myocardial infarction (MI) is a major component of cardiovascular disease. The primary challenge in MI therapy the lack energy affected tissue. Extracellular vesicles (EVs) areengineered with adenosine triphosphate (ATP) and targeted an anti-myosin antibody (T-EV) to effectively deliver damaged myocardial tissue mitigate effects (MI). Furthermore, using vivo rat model evaluate cardiac repair, we compared function, infarct size, expression troponin α-actin four weeks after those healthy group. results indicate that, no treatment, use Target-ATP-EVs (T-ATP-EVs) enhances viability hypoxic cells by 46% reduces apoptosis 28%. In animal study, there was 26% increase left ventricular ejection fraction (LVEF) 28% decrease size group when this treatment applied. Additionally, levels increased approximately two-fold these engineered EVs. EVs were investigated as strategy ATP directly cardiomyocytes heart both vitro models. system described here cardiomyocyte survival marking significant advancement infarction.

Language: Английский

---

Novel lncRNAs LINC01221, RP11-472G21.2 and CRNDE are markers of differential expression in pediatric patients with T cell acute lymphoblastic leukemia

Cancer Cell International, Journal Year: 2024, Volume and Issue: 24(1)

Published: Feb. 9, 2024

Abstract Introduction Pediatric T-cell acute lymphoblastic leukemia (T-ALL) poses significant challenges due to its aggressive nature and resistance standard treatments. Long non-coding RNAs (lncRNAs) have emerged as potential biomarkers therapeutic targets in leukemia. This study aims characterize the lncRNA landscape pediatric T-ALL, identify specific lncRNAs signatures, assess their clinical relevance. Methods RNA sequencing was performed on T-ALL patient control samples. Differential expression analysis identified dysregulated mRNAs. Functional enrichment revealed roles of these cancer pathogenesis. Validation candidate conducted using real-time PCR. Clinical correlations were assessed, including associations with patients’ characteristics survival outcomes. Results Analysis 674 LINC01221 CRNDE showing most interactions progression pathways. indicated involvement apoptosis, survival, proliferation, metastasis. Top 10 based adjusted p value < 0.05 Fold Change > 2 selected for validation. Seven LINC01221, PCAT18, LINC00977, RP11-620J15.3, RP11-472G21.2, CTD-2291D10.4, showed correlation data. RP11-472G21.2 CTD-2291D10.4 highly expressed patients, RP11-620J15.3 correlating significantly better overall ( = 0.0007) at a median follow up 32 months. The further analysed B-ALL patients. Distinct signatures noted, distinguishing from healthy controls, lineage-specific overexpression 0.0001), 0.001) 0.04) T-ALL. Conclusion provides insights into offering diagnostic prognostic markers. emerges promising marker, distinct may aid differentiation subtypes. Further research larger cohorts is warranted validate findings advance personalized treatment strategies

Language: Английский

---

Advancements in small interfering RNAs therapy for acute lymphoblastic leukemia: promising results and future perspectives

Molecular Biology Reports, Journal Year: 2024, Volume and Issue: 51(1)

Published: June 14, 2024

Language: Английский

---

B‐Cell Chronic Lymphocytic Leukemia and B‐Cell Lymphomas: The Key Role of Micro and Long Noncoding RNAs

Journal of Clinical Pharmacy and Therapeutics, Journal Year: 2024, Volume and Issue: 2024(1)

Published: Jan. 1, 2024

B‐cell chronic malignancies, including lymphocytic leukemia and lymphomas, are among the most common blood malignancies. Conventional therapies for these lymphoproliferative diseases include chemotherapy radiotherapy. However, treating types of cancer is still challenging due to developing resistance drugs even novel agents like immunochemotherapy. Therefore, many studies underway clarify mechanisms involved in this phenomenon. Recently, role noncoding RNAs regulating gene expression has been well documented literature. microRNAs small that regulate at transcriptional posttranscriptional levels. Long cell differentiation tissue development via regulation. Several miRNAs stimulate activation normal or malignant B‐cells. Molecular assessments revealed relationship between up/downregulation different genes therapeutic resistance. Studies suggest dysregulation molecules could be missing link drugs. Serum levels can employed as a predictive biomarker diagnosis, prognosis, response treatment This study reviews long drug lymphomas.

Language: Английский

---

Molecular Signature of miR‐34a/NEAT‐1/p53 Axis in Mycosis Fungoides

Dermatology Research and Practice, Journal Year: 2024, Volume and Issue: 2024(1)

Published: Jan. 1, 2024

Background . Mycosis fungoides (MF) is a type of cutaneous T‐cell lymphoma where red rash exists on the skin. Understanding role miRNAs and ncRNAs in p53‐response has become an open discussion, as they can regulate p53 or its downstream targets, themselves. Objectives To evaluate serum levels NEAT‐1, miR‐34a, MF patients relation to healthy controls indicate whether it potential pathogenesis disease. Subjects Methods This prospective case‐control study was carried out 75 subjects subdivided into two groups, 35 (stages 1 II) 40 matched controls. Their clinical investigations biomarkers (NEAT‐1, p53) were measured. Results There significant elevations expression both NEAT‐1 (5.10 ± 1.16) (277.28 62.02) comparison with (1.01 0.031) (194.29 16.039), respectively, while level miR‐34a tends decrease (0.24 0.15). are no difference between stages p53, there differences p value <0.05 biomarkers. positive correlation %BSA slightly P53 ( r = 0.353, 0.037) 0112, 0.05), respectively. also negative correlations disease duration −0.341, 0.045) B2 microglobulin −0.373, 0.027). Conclusion The combination may be considered that play active process for helping early diagnosis stage identification well.

Language: Английский

---

NEAT1 and CHROMR lncRNAs: a promising diagnostic tool for diffuse large B-cell lymphoma especially in elderly patients

Biomarkers in Medicine, Journal Year: 2024, Volume and Issue: 18(15-16), P. 685 - 693

Published: Aug. 17, 2024

Long non-coding (lnc) RNAs have crucial regulatory roles in molecular pathways, and their dysregulation is associated with the pathogenesis of malignancies such as Diffuse large B-cell lymphoma (DLBCL). Therefore, we aimed to study NEAT1 CHROMR expression DLBCL explore association clinicopathological characteristics.

Language: Английский

---

Immunoinformatics approach: Developing a multi‐epitope vaccine with novel carriers targeting monkeypox virus

The FASEB Journal, Journal Year: 2024, Volume and Issue: 38(24)

Published: Dec. 13, 2024

Since May 2022, the global spread of monkeypox virus (MPXV) has presented a significant threat to public health. Despite this, there are limited preventive measures available. In this study, different computational tools were employed design multi-epitope vaccine targeting MPXV. Three key MPXV proteins, M1R, B6R, and F3L, chosen for epitope selection, guided by bioinformatic analyses identify immunodominant epitopes T- B-cell activation. To enhance immune stimulation facilitate targeted delivery specific cells, selected linked novel carriers, including extracellular domain cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), 12-mer Clec9a binding peptide (CBP-12), Toll-like receptor 2 (TLR2) ligand. The designed construct exhibited strong antigenicity along with nonallergenic nontoxic properties, favorable physicochemical characteristics. validated vaccine's tertiary structure underwent evaluation interactions CD80/86, Clec9a, TLR2 through molecular docking dynamics simulation. results ensured stability high affinity aforementioned receptors. silico simulations studies revealed robust innate adaptive responses, enhanced mucosal immunity essential protection against Ultimately, DNA sequence was synthesized successfully cloned into pET-22b(+) vector. Our integration predictions, suggests proposed potential efficacy in safeguarding MPXV; however, further vitro vivo validations imperative assess real-world effectiveness safety.

Language: Английский

---

Immune checkpoints and ncRNAs: pioneering immunotherapy approaches for hematological malignancies

Cancer Cell International, Journal Year: 2024, Volume and Issue: 24(1)

Published: Dec. 19, 2024

Language: Английский

---